The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates
Open Access
- 1 June 2005
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (11) , 6909-6917
- https://doi.org/10.1128/jvi.79.11.6909-6917.2005
Abstract
Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only laboratory isolates, or have low potency. The most potent of these is C108g, directed against a type-specific epitope in HXB2 and BaL gp120s, which is glycan dependent and, in contrast to previous reports, dependent on intact disulfide bonds. This epitope was introduced into two primary Envs, derived from a neutralization-sensitive (SF162) and a neutralization-resistant (JR-FL) isolate, by substitution of two residues and, for SF162, addition of an N-linked glycosylation site. C108g effectively neutralized both variant Envs with considerably higher potency than standard MAbs against the V3 and CD4-binding domains and the broadly neutralizing MAbs 2G12 and 2F5. These amino acid substitutions also introduced the epitope recognized by a second V2-specific MAb, 10/76b, but this MAb possessed potent neutralizing activity only in the absence of the glycan required for C108g reactivity. In contrast to other gp120-specific neutralizing MAbs, C108g did not block binding of soluble Env proteins to either the CD4 or the CCR5 receptor, but studies with a fusion-arrested Env indicated that C108g neutralized at a step preceding the one blocked by the gp41-specific MAb, 2F5. These results indicate that the V1/V2 domain possesses targets that mediate potent neutralization of primary viral isolates via a novel mechanism and suggest that inclusion of carbohydrate determinants into these epitopes may help overcome the indirect masking effects that limit the neutralizing potency of antibodies commonly produced after infection.Keywords
This publication has 66 references indexed in Scilit:
- Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of SpecificitiesJournal of Virology, 2003
- Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce FusionJournal of Virology, 2003
- Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 PseudovirionsJournal of Virology, 2003
- Antibody neutralization and escape by HIV-1Nature, 2003
- Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1Journal of Virology, 2002
- Alterations in the V1/V2 Domain of HIV-2CBL24Glycoprotein 105 Correlate with an Extended Cell TropismAIDS Research and Human Retroviruses, 1999
- The V1/V2 Region of Human Immunodeficiency Virus Type 1 Modulates the Sensitivity to Neutralization by Soluble CD4 and Cellular TropismAIDS Research and Human Retroviruses, 1997
- CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5Nature, 1996
- Soluble CD4 Induces the Binding of Human Immunodeficiency Virus Type 1 to Cells via the V3 Loop of Glycoprotein 120 and Specific Sites in Glycoprotein 41AIDS Research and Human Retroviruses, 1996
- Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1Molecular Immunology, 1995